

Orforglipron
Oral semaglutide 25 mg (Wegovy pill)
S0 Primary (time-matched, pooled injectables)
S1 Health-professional reports only
S2 Consumer reports only
S3 Obesity/weight indication only
S4 US reports only
S5 Comparator: injectable semaglutide only
S6 Comparator: tirzepatide only
S7 Masking: reports with GI events removed
S8 Comparator includes all 2024-2026 injectable reports
S9 Loose duplicate rule applied
S10 Spontaneous reports only (solicited/study reports excluded)
S11 Launch-phase comparator: Zepbound, Jan-Jun 2024 (Weber effect)
S12 Batch-transmission days excluded (>=50 index reports/day)
2.4* 1.5* 1.9* 1.0 0.7 0.7 3.4*
4.1* 1.3 1.5* 1.0 0.5 1.4 2.2*
2.2* 1.6* 2.0* 1.0 0.8 0.7 3.8*
1.9* 1.2 1.6* 0.8 0.6 0.5 2.6*
2.3* 1.5* 2.1* 1.1 0.9 0.7 3.0*
2.8* 1.5* 1.9* 1.1 0.5 1.6* 2.9*
2.2* 1.5* 2.0* 0.9 0.9 0.5 3.8*
2.2* 2.6* 1.4* 1.0 0.8 6.0*
2.9* 1.9* 2.1* 1.1 0.7 0.8 5.0*
2.2* 1.4* 1.8* 0.9 0.7 0.7 3.3*
2.4* 1.5* 2.0* 1.0 0.7 0.7 3.4*
4.9* 3.2* 3.9* 1.7* 1.2 2.4* 11.3*
2.5* 1.6* 1.9* 0.9 0.7 0.6 3.3*
1.4* 1.1 1.5* 2.0* 1.3 0.4 4.0*
1.5* 0.9 1.1 2.5* 0.9 0.4 3.0*
1.4* 1.2 1.6* 1.7* 1.5* 0.4 4.5*
1.1 1.1 1.4* 1.7* 1.5* 0.4 3.6*
1.4* 1.1 1.7* 2.1* 1.5* 0.3 3.9*
1.6* 1.1 1.5* 2.3* 1.0 1.0 3.6*
1.3* 1.2 1.6* 1.9* 1.6* 0.3 4.2*
0.9 1.4 2.5* 1.3 0.4 5.0*
1.6* 1.4* 1.7* 2.1* 1.3 0.5 5.5*
1.3* 1.0 1.4* 1.8* 1.2 0.4 4.0*
1.4* 1.1 1.6* 1.9* 1.4* 0.4 4.0*
2.8* 2.3* 3.0* 3.5* 2.3* 1.4 12.5*
1.3* 1.2 1.5* 1.9* 1.2 0.4 3.7*
Gastrointestinal intolerance
Fatigue/ asthenia
Dizziness/ headache
Hypersensitivity
Psychiatric
Hair loss
Non-response
log₂ ROR
3
2
1
0
−1
−2
−3